HBM HOLDINGS-B(02142)

14.000-0.120-0.85%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Undiscovered Gems in Asia To Explore This January 2026
  Simply Wall St. · 01-09 12:03
  Undiscovered Gems in Asia To Explore This January 2026
- HBM HOLDINGS-B (02142) Rises Over 3% as Jointly Submitted Pancreatic Cancer Research Project with Changhai Hospital Gains Major National Science and Technology Innovation Grant
  Stock News · 01-07
  HBM HOLDINGS-B (02142) Rises Over 3% as Jointly Submitted Pancreatic Cancer Research Project with Changhai Hospital Gains Major National Science and Technology Innovation Grant
- CICC Maintains Outperform Rating on HBM HOLDINGS-B (02142), Raises Target Price to HK$18
  Stock News · 01-07
  CICC Maintains Outperform Rating on HBM HOLDINGS-B (02142), Raises Target Price to HK$18
- HBM Holdings Files Next Day Disclosure to HKEX After Repurchasing 100,000 Shares for HKD 1.22 Million
  Reuters · 01-02
  HBM Holdings Files Next Day Disclosure to HKEX After Repurchasing 100,000 Shares for HKD 1.22 Million
- HBM HOLDINGS-B (02142) Grants 309,000 Share Options
  Stock News · 01-01
  HBM HOLDINGS-B (02142) Grants 309,000 Share Options
- HBM Holdings Grants Share Options to Employee Under Existing Scheme
  Reuters · 01-01
  HBM Holdings Grants Share Options to Employee Under Existing Scheme
- Zhixiang Hong Kong Stock Repurchase Statistics | January 1
  Stock News · 01-01
  Zhixiang Hong Kong Stock Repurchase Statistics | January 1
- HBM Holdings Files HKEX Disclosure on Repurchase of 100,000 Shares for HKD 1.22 Million
  Reuters · 2025-12-31
  HBM Holdings Files HKEX Disclosure on Repurchase of 100,000 Shares for HKD 1.22 Million
- HBM HOLDINGS-B (02142) Repurchases 300,000 Shares for HK$3.6305 Million on December 30
  Stock News · 2025-12-30
  HBM HOLDINGS-B (02142) Repurchases 300,000 Shares for HK$3.6305 Million on December 30
- Harbour BioMed and Lannacheng Launch Strategic Collaboration on Next-Generation Radionuclide Drug Conjugates
  Reuters · 2025-12-29
  Harbour BioMed and Lannacheng Launch Strategic Collaboration on Next-Generation Radionuclide Drug Conjugates
- Harbour Biomed Enters Into Long-Term Strategic Collaboration With Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
  THOMSON REUTERS · 2025-12-29
  Harbour Biomed Enters Into Long-Term Strategic Collaboration With Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
- HBM Holdings (SEHK:2142): Valuation Check After Bristol Myers Squibb Collaboration Validates Growth Prospects
  Simply Wall St. · 2025-12-20
  HBM Holdings (SEHK:2142): Valuation Check After Bristol Myers Squibb Collaboration Validates Growth Prospects
- HK Stock Movement | HBM Holdings-B (02142) Surges Over 8% in Early Trading on $1B+ BD Deal with Bristol-Myers Squibb
  Stock News · 2025-12-19
  HK Stock Movement | HBM Holdings-B (02142) Surges Over 8% in Early Trading on $1B+ BD Deal with Bristol-Myers Squibb
- HK Stock Movement | HBM HOLDINGS-B (02142) Still Down 2% After Signing Global Strategic Collaboration with Bristol-Myers Squibb, Potential Earnings Exceed $1 Billion
  Stock News · 2025-12-17
  HK Stock Movement | HBM HOLDINGS-B (02142) Still Down 2% After Signing Global Strategic Collaboration with Bristol-Myers Squibb, Potential Earnings Exceed $1 Billion
- Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
  Reuters · 2025-12-17
  Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
- HBM Holdings and Bristol Myers Squibb Sign Global Strategic Collaboration Agreement
  Reuters · 2025-12-17
  HBM Holdings and Bristol Myers Squibb Sign Global Strategic Collaboration Agreement
- Hbm Holdings - Entering Into Global Strategic Collaboration and License Agreement With Bristol Myers Squibb
  THOMSON REUTERS · 2025-12-17
  Hbm Holdings - Entering Into Global Strategic Collaboration and License Agreement With Bristol Myers Squibb
- Hbm Holdings - Under Deal, Co to Collaborate to Advance and Accelerate Multi-Specific Antibody Discovery Programs
  THOMSON REUTERS · 2025-12-17
  Hbm Holdings - Under Deal, Co to Collaborate to Advance and Accelerate Multi-Specific Antibody Discovery Programs
- Hbm Holdings - Could Receive Payments Totaling $90 Mln & Development and Commercial Milestones of up to $1,035 Mln Under Deal
  THOMSON REUTERS · 2025-12-17
  Hbm Holdings - Could Receive Payments Totaling $90 Mln & Development and Commercial Milestones of up to $1,035 Mln Under Deal
- Declining Stock and Solid Fundamentals: Is The Market Wrong About HBM Holdings Limited (HKG:2142)?
  Simply Wall St. · 2025-12-17
  Declining Stock and Solid Fundamentals: Is The Market Wrong About HBM Holdings Limited (HKG:2142)?
Company Profile
Company Name
HBM HOLDINGS-B
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
- -
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.

1D
5D
Day
Week
Month

Loading ...

High

14.320

Open

14.290

Volume%

0.55

Low

13.780

14.120

T/O Rate

0.40%

To The Moon

HBM HOLDINGS-B(02142)

Company Profile

Most Discussed